Comparative efficacy of phase 2-3 therapies for non-cirrhotic metabolic dysfunction-associated steatohepatitis: An updated network meta-analysis
Newer metabolic drugs show promise against fatty liver disease, though combination approaches may be needed since many patients don't respond to single agents.
This comprehensive network meta-analysis compared all phase 2-3 MASH therapies across 64 trials and found that metabolic pathway-targeting drugs (especially FGF21 analogs and incretin-based multi-agonists) consistently outperformed other classes. However, absolute non-response remained high at 35-70%, highlighting the need for combination approaches.
What the study was
- Study design
- Network meta-analysis of phase 2-3 RCTs
- Population
- Non-cirrhotic MASH patients across 64 phase 2-3 trials
- Sample size
- 12787
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- Med
Why it surfaced
Most comprehensive NMA of MASH therapies to date, directly informs rational drug selection and combination strategies in a rapidly evolving therapeutic landscape.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.